Results 171 to 180 of about 457,600 (353)

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation [PDF]

, 2017
Galemmo, Robert A, Jr, Han, Zhenfu, Janetka, James W, Klampfer, Lidija, Owusu, Benjamin Y, Thomas, Shantasia, Venukadasula, Phanindra   +6 more
core   +2 more sources

Tyrosine kinase inhibitors [PDF]

Cancer Cell, 2004
Arteaga, Carlos L., Baselga, Jose
openaire   +1 more source

Type II Alveolar Epithelial Cells Promote Sepsis‐Induced Immunosuppression in Alveolar Macrophages via Exosomal lncRNA Rmrp Release

Advanced Science, EarlyView.
The S100A4/STAT3 axis promotes Rmrp transcription in AEC‐IIs and Rmrp expression in AEC‐II‐derived exosomes. Upon entry into AMs, Rmrp binds to and blocks the ubiquitination and degradation of ZFP36. Increased ZFP36 induced Pfkfb3 mRNA decay by binding to AREs in the 3′ UTR, curbing glycolysis and immune responses of AMs and aggravating SII and ...
Chengxi Liu, Weixia Xuan, Song Cao, Huayun Jia, Qian Wu, Xiaowu Tan, Qijie Wang, Xiaojun Li, Lisha Ding, Yaru Xiong, Meiyun Zhao, Longcheng Zheng, Yunzhu Xi, Jianhua Tan, Rong Li, Xulong Zhang, Wenjie Liu, Xu Wu   +17 more
wiley   +1 more source

Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]

, 2015
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte, Dane E. Karr, Danny Tam, David Finkle, David G. Loughhead, David M. Goldstein, Erik Verner, J. Hill, J. Michael Bradshaw, Jack Taunton, Jens Oliver Funk, Jesse M. Mcfarl, Jin Shu, Ken A. Brameld, Mary E, Philip A. Nunn, Principia Biopharma, Sergei Romanov, Timothy D. Owens, Tony Ton, Vaishali Patel, Vernon T. Phan, Ville O. Paavilainen, Xiaoyan Li   +23 more
core  

Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy

, 2018
Mark Fairweather, Michael J. Cavnar, G Z Li, Monica M. Bertagnolli, Ronald P. DeMatteo, Chandrajit P. Raut   +5 more
openalex   +2 more sources

CircPVT1 Promotes Lung Metastasis and Tumor Progression in Renal Cell Carcinoma by Encoding the cP104aa Peptide and Targeting EIF4A3

Advanced Science, EarlyView.
This study reveals that circPVT1 promotes the renal cell carcinoma lung metastasis and tumor progression through encoding the cP104aa peptide and directly binds with EIF4A3, which jointly regulates the target gene c‐MYC. Abstract Circular RNA (circRNA) plays a pivotal role in the pathogenesis of renal cell carcinoma (RCC).
Houliang Zhang, Tao Tao, Jie Ji, Tonglei Zhao, Si Sun, Lijie Zhang, Jianping Wu, Ming Chen, Shuqiu Chen, Bin Xu, Weipu Mao   +10 more
wiley   +1 more source

29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results

, 2022
Marcello Tiseo, Sanjay Popat, Hye Ryun Kim, M-J. Ahn, Jin Yang, J-Y. Han, Maximilian J. Hochmair, K.H. Lee, Angelo Delmonte, M.R. García Campelo, Dongwook Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, A.I. Spira, Scott Gettinger, Huimin Lin, Y. Liu, Florin Vranceanu, D. Ross Camidge   +19 more
openalex   +2 more sources

NNMT Orchestrates Metabolic‐Epigenetic Reprogramming to Drive Macrophage‐Myofibroblast Transition in Hypertrophic Scarring

Advanced Science, EarlyView.
In macrophage‐myofibroblast transition, upregulated NNMT depletes S‐Adenosylmethionine‌ (SAM) and nicotinamide adenine dinucleotide(NAD+), thereby triggering epigenetic reprogramming via Histone H3 Lysine 27 acetylation (H3K27ac) accumulation at the promoter region of master transcription factor Prrx1.
Xiwen Dong, Weinan Guo, Yuxuan Qian, Wenyan Jin, Xiaozhen Li, Jingyuan Yang, Qingrong Ni, Shuang Wu, Fanni Li, Hua Wang, Chunying Li, Hong Cai   +11 more
wiley   +1 more source

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Efficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook, Piers Patten, Nicholas Peckham, Paul Moss, Abhishek Abhishek, Vicki S Barber, Anne Francis, Lelia Duley, Robbert Hoogeboom, Brian J Willett, Gratian Vandici, Gareth Plested, Lucy Eldridge, Patrick Julier, Thomas Roberts, Marie Hodges, Helen M Parry   +16 more
doaj   +1 more source

[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].

, 2020
Nobuaki Dobashi
openalex   +2 more sources